MCID: RTN015
MIFTS: 46

Retinal Cancer

Categories: Cancer diseases, Eye diseases, Neuronal diseases

Aliases & Classifications for Retinal Cancer

MalaCards integrated aliases for Retinal Cancer:

Name: Retinal Cancer 12 15
Malignant Neoplasm of Retina 12 73
Retinal Neoplasms 44 73
Malignant Retinal Neoplasm 12
Malignant Tumor of Retina 12
Neoplasm of Retina 12
Retinal Tumor 12

Classifications:



External Ids:

Disease Ontology 12 DOID:4645
ICD10 33 C69.2
ICD9CM 35 190.5
MeSH 44 D019572
NCIt 50 C3216 C4800
SNOMED-CT 68 93987004

Summaries for Retinal Cancer

MalaCards based summary : Retinal Cancer, also known as malignant neoplasm of retina, is related to retinoblastoma and vulvar adenocarcinoma. An important gene associated with Retinal Cancer is RB1 (RB Transcriptional Corepressor 1), and among its related pathways/superpathways are Signaling by GPCR and ERK Signaling. The drugs Vincristine and Etoposide have been mentioned in the context of this disorder. Affiliated tissues include retina, eye and lung, and related phenotypes are Increased shRNA abundance (Z-score > 2) and Increased shRNA abundance (Z-score > 2)

Wikipedia : 76 Retinoblastoma (Rb) is a rare form of cancer that rapidly develops from the immature cells of a retina,... more...

Related Diseases for Retinal Cancer

Diseases related to Retinal Cancer via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 143)
# Related Disease Score Top Affiliating Genes
1 retinoblastoma 30.5 CCND1 CCND3 CDK2 CDK4 CDK6 CDKN1A
2 vulvar adenocarcinoma 10.3 RB1 TP53
3 breast papillomatosis 10.3 CCND1 CDKN2A
4 glioblastoma proneural subtype 10.3 CDK4 CDK6
5 tonsil squamous cell carcinoma 10.3 CCND1 CDKN2A
6 ewing's family of tumors 10.3 CDK4 CDKN2A RB1
7 unilateral retinoblastoma 10.3 RB1 RBL1
8 zika virus infection 10.3 MDM2 TP53
9 endometrial squamous cell carcinoma 10.3 CCND1 CDK6 CDKN2A
10 gallbladder adenoma 10.3 CDKN2A RB1
11 pre-malignant neoplasm 10.3 CCND1 CDKN2A TP53
12 bladder squamous cell carcinoma 10.3 CDKN2A TP53
13 laryngeal disease 10.3 CCND1 CDKN2A TP53
14 oropharynx cancer 10.3 CCND1 CDKN2A TP53
15 chondromyxoid fibroma 10.3 CCND1 CDKN1A CDKN2A
16 spindle cell lipoma 10.3 CDK4 MDM2 RB1
17 penile cancer 10.3 CCND1 CDKN2A TP53
18 esophageal disease 10.3 CCND1 CDKN2A TP53
19 ring chromosome 7 10.3 CDK4 MDM2 TP53
20 splenic diffuse red pulp small b-cell lymphoma 10.3 CCND3 TP53
21 hepatic angiomyolipoma 10.3 MYC RB1
22 bladder carcinoma in situ 10.3 CCND3 CDKN2A TP53
23 keratinizing squamous cell carcinoma 10.3 CDKN2A TP53
24 undifferentiated embryonal sarcoma of the liver 10.2 CDK4 MDM2
25 tonsil cancer 10.2 CDKN1B CDKN2A TP53
26 infiltrating angiolipoma 10.2 CDK4 CDKN2A MDM2
27 uterine anomalies 10.2 CCND1 CDKN2A TP53
28 cervical adenocarcinoma 10.2 CDKN1A CDKN2A TP53
29 megaesophagus 10.2 CDKN2A MYC TP53
30 bladder disease 10.2 CCND1 CDKN2A TP53
31 invasive bladder transitional cell carcinoma 10.2 CDKN1A TP53
32 atypical lipomatous tumor 10.2 CDK4 CDKN2A MDM2
33 periosteal osteogenic sarcoma 10.2 CDK4 MDM2 TP53
34 cervix carcinoma 10.2 CDKN2A CDKN3 TP53
35 small cell sarcoma 10.2 CDK4 MDM2 TP53
36 actinic cheilitis 10.2 CDKN1A MDM2 TP53
37 multiple endocrine neoplasia, type iv 10.2 CDK2 CDKN1B CDKN3
38 well-differentiated liposarcoma 10.2 CDK4 CDKN2A MDM2
39 embryonal sarcoma 10.2 CDK4 MDM2 TP53
40 bladder transitional cell papilloma 10.2 CDKN1A TP53
41 lip cancer 10.2 CDKN1A MDM2 TP53
42 laryngeal squamous cell carcinoma 10.2 CCND1 CDKN2A TP53
43 bowenoid papulosis 10.2 CCND1 CDKN2A
44 oral cancer 10.2 CCND1 CDKN2A TP53
45 connective tissue cancer 10.2 CDK4 MDM2 TP53
46 female reproductive system disease 10.2 CCND1 CDKN2A TP53
47 cellular schwannoma 10.2 CDKN2A MDM2 TP53
48 malignant fibrous histiocytoma of bone 10.2 CDK4 MDM2 MYC
49 myxoid liposarcoma 10.2 CDK4 MDM2 TP53
50 leukocyte disease 10.2 CCND1 MYC TP53

Graphical network of the top 20 diseases related to Retinal Cancer:



Diseases related to Retinal Cancer

Symptoms & Phenotypes for Retinal Cancer

GenomeRNAi Phenotypes related to Retinal Cancer according to GeneCards Suite gene sharing:

26 (show all 38)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased shRNA abundance (Z-score > 2) GR00366-A-118 10.46 CDK2 MDM2
2 Increased shRNA abundance (Z-score > 2) GR00366-A-122 10.46 CDK2
3 Increased shRNA abundance (Z-score > 2) GR00366-A-126 10.46 CCND1
4 Increased shRNA abundance (Z-score > 2) GR00366-A-13 10.46 CDK2
5 Increased shRNA abundance (Z-score > 2) GR00366-A-136 10.46 MDM2
6 Increased shRNA abundance (Z-score > 2) GR00366-A-151 10.46 MDM2
7 Increased shRNA abundance (Z-score > 2) GR00366-A-152 10.46 CCND1
8 Increased shRNA abundance (Z-score > 2) GR00366-A-157 10.46 CDK2 MDM2
9 Increased shRNA abundance (Z-score > 2) GR00366-A-16 10.46 CCND1
10 Increased shRNA abundance (Z-score > 2) GR00366-A-163 10.46 CCND1
11 Increased shRNA abundance (Z-score > 2) GR00366-A-176 10.46 MDM2
12 Increased shRNA abundance (Z-score > 2) GR00366-A-177 10.46 CCND1
13 Increased shRNA abundance (Z-score > 2) GR00366-A-178 10.46 MYC
14 Increased shRNA abundance (Z-score > 2) GR00366-A-199 10.46 CCND1
15 Increased shRNA abundance (Z-score > 2) GR00366-A-21 10.46 CCND1
16 Increased shRNA abundance (Z-score > 2) GR00366-A-210 10.46 CCND1
17 Increased shRNA abundance (Z-score > 2) GR00366-A-24 10.46 MYC
18 Increased shRNA abundance (Z-score > 2) GR00366-A-25 10.46 CCND1 CDK2 MDM2 MYC
19 Increased shRNA abundance (Z-score > 2) GR00366-A-36 10.46 CCND1
20 Increased shRNA abundance (Z-score > 2) GR00366-A-41 10.46 CDK2
21 Increased shRNA abundance (Z-score > 2) GR00366-A-43 10.46 CDK2 MDM2
22 Increased shRNA abundance (Z-score > 2) GR00366-A-49 10.46 CDK2
23 Increased shRNA abundance (Z-score > 2) GR00366-A-57 10.46 CDK2
24 Increased shRNA abundance (Z-score > 2) GR00366-A-67 10.46 MDM2
25 Increased shRNA abundance (Z-score > 2) GR00366-A-73 10.46 MYC
26 Increased shRNA abundance (Z-score > 2) GR00366-A-93 10.46 CDK2
27 Decreased viability GR00221-A-1 10.41 CDK6 CDKN1B CDKN2A E2F1 MYC RBL1
28 Decreased viability GR00221-A-2 10.41 CDK6 E2F1 RBL1
29 Decreased viability GR00221-A-3 10.41 CDKN2A MYC
30 Decreased viability GR00221-A-4 10.41 CDK6 CDKN2A
31 Decreased viability GR00301-A 10.41 CDK6
32 Decreased viability GR00402-S-2 10.41 CDK6 CDKN1B CDKN2A E2F1 MYC RBL1
33 Decreased influenza A/WSN/33 replication GR00195-A-1 9.71 CDKN1B E2F1 MDM2 MYC
34 Increased viability with MLN4924 (a NAE inhibitor) GR00250-A-3 9.63 CDK2 CDKN1A CDKN1B E2F3 MDM2 TP53
35 Increased cell death in breast cancer cell lines (MCF10A, MDA-MB-435) GR00104-A-0 9.62 CCND1 CDKN3 E2F3 RBL1
36 Reduced mammosphere formation GR00396-S 9.5 CCND1 CCND3 CDK4 CDK6 E2F2 MDM2
37 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-1 9.47 CDK2 CDKN1A CDKN2A E2F1 RB1 TP53
38 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-2 9.47 CCND1 CDK2 CDKN1A CDKN2A E2F1 MYC

MGI Mouse Phenotypes related to Retinal Cancer:

46 (show all 28)
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.56 CCND1 CCND3 CDK2 CDK4 CDK6 CDKN1A
2 cellular MP:0005384 10.55 CCND1 CDK2 CDK4 CDK6 CDKN1A CDKN1B
3 endocrine/exocrine gland MP:0005379 10.55 CCND1 CCND3 CDK2 CDK4 CDK6 CDKN1A
4 growth/size/body region MP:0005378 10.55 CCND1 CCND3 CDK2 CDK4 CDK6 CDKN1A
5 immune system MP:0005387 10.49 CCND1 CCND3 CDK2 CDK4 CDK6 CDKN1A
6 mortality/aging MP:0010768 10.49 CCND1 CCND3 CDK2 CDK4 CDK6 CDKN1A
7 behavior/neurological MP:0005386 10.48 CCND1 CCND3 CDK4 CDKN1A CDKN1B CDKN2A
8 embryo MP:0005380 10.48 CDK2 CDK4 CDK6 CDKN1A CDKN1B CDKN2A
9 hematopoietic system MP:0005397 10.48 CCND1 CCND3 CDK2 CDK4 CDK6 CDKN1A
10 homeostasis/metabolism MP:0005376 10.47 CCND1 CCND3 CDK2 CDK4 CDKN1A CDKN1B
11 integument MP:0010771 10.45 CCND1 CDK2 CDK4 CDKN1A CDKN1B CDKN2A
12 digestive/alimentary MP:0005381 10.42 CCND1 CDK4 CDKN1A CDKN1B CDKN2A E2F1
13 neoplasm MP:0002006 10.41 CCND1 CCND3 CDK2 CDK4 CDK6 CDKN1A
14 craniofacial MP:0005382 10.36 CCND1 CDKN1A CDKN1B E2F1 E2F4 MDM2
15 liver/biliary system MP:0005370 10.34 CCND3 CDK2 CDK4 CDK6 CDKN1A CDKN1B
16 muscle MP:0005369 10.31 CDK2 CDK4 CDK6 CDKN1A CDKN1B CDKN2A
17 nervous system MP:0003631 10.3 CCND1 CDK4 CDKN1A CDKN1B CDKN2A E2F1
18 adipose tissue MP:0005375 10.24 CDKN1A CDKN1B E2F1 E2F3 MYC RB1
19 hearing/vestibular/ear MP:0005377 10.24 CDKN1A CDKN1B E2F1 E2F4 MYC RB1
20 normal MP:0002873 10.22 CCND1 CCND3 CDK4 E2F1 E2F2 E2F3
21 reproductive system MP:0005389 10.16 CCND1 CDK2 CDK4 CDK6 CDKN1A CDKN1B
22 no phenotypic analysis MP:0003012 10.13 CDKN1A CDKN1B CDKN2A E2F3 MDM2 MYC
23 limbs/digits/tail MP:0005371 10.08 CDKN1A MDM2 MYC RB1 RBL1 RBL2
24 renal/urinary system MP:0005367 9.97 CDK4 CDKN1A CDKN1B E2F2 MDM2 RB1
25 respiratory system MP:0005388 9.97 CCND1 CCND3 CDKN1A CDKN1B CDKN2A E2F1
26 pigmentation MP:0001186 9.91 CDK4 CDKN1B CDKN2A MDM2 MYC RB1
27 skeleton MP:0005390 9.77 CCND1 CDKN1A CDKN1B CDKN2A E2F1 E2F3
28 vision/eye MP:0005391 9.47 CCND1 CCND3 CDK2 CDK4 CDKN1A CDKN1B

Drugs & Therapeutics for Retinal Cancer

Drugs for Retinal Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 163)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Vincristine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 57-22-7, 2068-78-2 5978
2
Etoposide Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 33419-42-0 36462
3
Carboplatin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 41575-94-4 10339178 38904 498142
4
Itraconazole Approved, Investigational Phase 4 84625-61-6 55283
5
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 1 22916-47-8 4189
6
Lenograstim Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 135968-09-1
7
Nicotine Approved Phase 4 54-11-5 942 89594
8 Etoposide phosphate Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
9 Topoisomerase Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
10 Antineoplastic Agents, Phytogenic Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
11 Antimitotic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
12 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
13 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
14 Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
15 Hormones Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
16 Immunologic Factors Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable,Early Phase 1
17 Cytochrome P-450 CYP3A Inhibitors Phase 4
18 Steroid Synthesis Inhibitors Phase 4,Phase 3,Phase 2,Phase 1
19 Cytochrome P-450 Enzyme Inhibitors Phase 4
20
Hydroxyitraconazole Phase 4
21 Antifungal Agents Phase 4,Phase 2,Phase 1
22 Adjuvants, Immunologic Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
23
Cisplatin Approved Phase 3,Phase 2,Not Applicable 15663-27-1 2767 441203 84093
24
Palbociclib Approved, Investigational Phase 3,Phase 2,Phase 1 571190-30-2 11431660 5330286 5005498
25
Iodine Approved, Investigational Phase 3,Phase 2,Phase 1 7553-56-2 807
26
Topotecan Approved, Investigational Phase 3,Phase 1,Phase 2,Not Applicable 123948-87-8, 119413-54-6 60700
27
Cyclophosphamide Approved, Investigational Phase 3,Phase 2,Phase 1,Early Phase 1 6055-19-2, 50-18-0 2907
28
Thiotepa Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable 52-24-4 5453
29
Doxorubicin Approved, Investigational Phase 3,Phase 2 23214-92-8 31703
30
Mesna Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable 3375-50-6 598
31
Letrozole Approved, Investigational Phase 3,Phase 2,Phase 1 112809-51-5 3902
32
Doxil Approved June 1999 Phase 3,Phase 2 31703
33 Immunosuppressive Agents Phase 3,Phase 1,Phase 2,Not Applicable,Early Phase 1
34 Alkylating Agents Phase 3,Phase 1,Phase 2,Not Applicable,Early Phase 1
35 Antineoplastic Agents, Alkylating Phase 3,Phase 1,Phase 2,Not Applicable,Early Phase 1
36 Protein Kinase Inhibitors Phase 3,Phase 2,Phase 1
37 cadexomer iodine Phase 3,Phase 2,Phase 1
38 Micronutrients Phase 3,Phase 2
39 Trace Elements Phase 3,Phase 2
40 Anti-Infective Agents, Local Phase 3,Phase 2
41 topoisomerase I inhibitors Phase 3,Phase 2,Phase 1,Not Applicable
42 Antirheumatic Agents Phase 3,Phase 2,Phase 1,Early Phase 1
43 Anesthetics Phase 3,Phase 2,Not Applicable,Early Phase 1
44 Antibiotics, Antitubercular Phase 3,Phase 2,Phase 1
45 Anti-Bacterial Agents Phase 3,Phase 2,Phase 1,Early Phase 1
46 Estrogen Antagonists Phase 3,Phase 2,Phase 1
47 Estrogens Phase 3,Phase 2,Phase 1
48 Aromatase Inhibitors Phase 3,Phase 2,Phase 1
49 Estrogen Receptor Antagonists Phase 3,Phase 2,Phase 1
50 Keratolytic Agents Phase 3

Interventional clinical trials:

(show top 50) (show all 121)
# Name Status NCT ID Phase Drugs
1 CEV With/Without Periocular Carboplatin Chemotherapy for Extraocular Retinoblastoma Completed NCT02319486 Phase 4 carboplatin periocular injection;CEV chemotherapy
2 Efficacy of Prophylactic Itraconazole in High-Dose Chemotherapy and Autologous Hematopoietic Stem Cell Transplantation Completed NCT00336531 Phase 4 itraconazole
3 G-CSF Alone or Combination With GM-CSF on Prevention and Treatment of Infection in Children With Malignant Tumor Recruiting NCT02933333 Phase 4
4 Carboplatin Periocular Injection for Retinoblastoma Unknown status NCT02137928 Phase 3 carboplatin periocular injection;chemotherapy
5 Neoadjuvant Carboplatin and Vincristine and Standard Local Ophthalmic Therapy in Treating Patients With Intraocular Retinoblastoma Completed NCT00079417 Phase 3 carboplatin;vincristine sulfate
6 Vincristine, Carboplatin, and Etoposide or Observation Only in Treating Patients Who Have Undergone Surgery for Newly Diagnosed Retinoblastoma Completed NCT00335738 Phase 3 liposomal vincristine sulfate;carboplatin;etoposide
7 Treatment Protocol for Non-Metastatic Unilateral Retinoblastoma Recruiting NCT03475121 Phase 3
8 Adjuvant Chemotherapy for High-risk Retinoblastoma After Enucleation Recruiting NCT01906814 Phase 3 3 cycles chemotherapy;6 cycles chemotherapy
9 Combination Chemotherapy, Autologous Stem Cell Transplant, and/or Radiation Therapy in Treating Young Patients With Extraocular Retinoblastoma Active, not recruiting NCT00554788 Phase 3 Carboplatin;Cisplatin;Cyclophosphamide;Etoposide;Thiotepa;Vincristine Sulfate
10 Study of Treatment for Patients With Cancer of the Eye -Retinoblastoma Active, not recruiting NCT00186888 Phase 3 Vincristine, Carboplatin;Vincristine + Topotecan;Vincristine + Carboplatin + Etoposide;Vincristine + Cyclophosphamide + Doxorubicin;Vincristine+Carboplatin+Etoposide
11 Study of Fixed vs. Flexible Filgrastim to Accelerate Bone Marrow Recovery After Chemotherapy in Children With Cancer Active, not recruiting NCT01987596 Phase 3
12 A Study of Palbociclib (PD-0332991) + Letrozole vs. Letrozole For 1st Line Treatment Of Postmenopausal Women With ER+/HER2- Advanced Breast Cancer (PALOMA-2) Active, not recruiting NCT01740427 Phase 3 PD-0332991;Letrozole;Placebo;Letrozole
13 Systemic Chemotherapy and Subtenon Carboplatin, and Local Ophthalmic Therapy in Children With Intraocular Retinoblastoma Terminated NCT00072384 Phase 3 liposomal vincristine sulfate;carboplatin;etoposide
14 Intra-arterial Chemotherapy for Children With Retinoblastoma Unknown status NCT00906113 Phase 1, Phase 2 Intra-arterial injection of melphalan;Injection of melphalan into the ophthalmic artery
15 Efficacy Study of Lucentis in the Treatment of Retinoblastoma Unknown status NCT01899066 Phase 2 Lucentis, chemotherapy;chemotherapy
16 Chemotherapy Treatment for Children With Intraocular Germ-Line Retinoblastoma Unknown status NCT00179920 Phase 2 Carboplatin;VP-16
17 Chemotherapy in Treating Patients With Retinoblastoma Completed NCT00002675 Phase 2 carboplatin;cisplatin;cyclophosphamide;etoposide;mesna;vincristine sulfate
18 Carboplatin Plus Vincristine in Treating Children With Retinoblastoma Completed NCT00002794 Phase 2 carboplatin;vincristine sulfate
19 Intra-arterial Chemotherapy(Chemosurgery) for Retinoblastoma Completed NCT00901238 Phase 1, Phase 2
20 Combination Chemotherapy, Radiation Therapy, and Bone Marrow Transplantation in Treating Patients With Retinoblastoma Completed NCT00004006 Phase 2 carboplatin;cyclophosphamide;doxorubicin hydrochloride;etoposide;topotecan hydrochloride
21 Cyclin Dependent Kinase (CDK)4/6 Inhibitor, PD0332991 in Advanced Non-small Cell Lung Cancer NSCLC. Completed NCT01291017 Phase 2 PD0332991
22 Rebeccamycin Analogue in Treating Children With Solid Tumors or Non-Hodgkin's Lymphoma Completed NCT00006102 Phase 2 becatecarin
23 Uncontrolled, Open Label, Pilot and Feasibility Study of Niacinamide in Polycystic Kidney Disease Completed NCT02140814 Phase 2
24 High-Dose Thiotepa Plus Peripheral Stem Cell Transplantation in Treating Patients With Refractory Solid Tumors Completed NCT00003173 Phase 2 thiotepa
25 Arsenic Trioxide in Treating Patients With Advanced Neuroblastoma or Other Childhood Solid Tumors Completed NCT00024258 Phase 2 arsenic trioxide
26 Cixutumumab in Treating Patients With Relapsed or Refractory Solid Tumors Completed NCT00831844 Phase 2
27 Combination Chemotherapy Followed by Bone Marrow Transplantation in Treating Patients With Rare Cancer Completed NCT00002515 Phase 2 carboplatin;thiotepa;topotecan hydrochloride
28 An Investigational Drug, Palbociclib (PD-0332991), Is Being Studied In Combination With Velcade And Dexamethasone In Patients With Multiple Myeloma. Patients Must Have Received Prior Treatment For Multiple Myeloma. Completed NCT00555906 Phase 2 Bortezomib;Dexamethasone;PD 0332991
29 Metformin Hydrochloride in Treating Patients With Prostate Cancer Undergoing Surgery Completed NCT01433913 Phase 2 metformin hydrochloride
30 Study Of Letrozole With Or Without Palbociclib (PD-0332991) For The First-Line Treatment Of Hormone-Receptor Positive Advanced Breast Cancer Completed NCT00721409 Phase 2 PD 0332991;letrozole;letrozole
31 A Study Of Oral Palbociclib (PD-0332991), A CDK4/6 Inhibitor, As Single Agent In Japanese Patients With Advanced Solid Tumors Or In Combination With Letrozole For The First-Line Treatment Of Postmenopausal Japanese Patients With ER (+) HER2 (-) Advanced Breast Cancer Completed NCT01684215 Phase 2 PD-0332991;PD-0332991;letrozole;PD-0332991;letrozole
32 Protocol for the Study and Treatment of Participants With Intraocular Retinoblastoma Recruiting NCT01783535 Phase 2 vincristine;topotecan;filgrastim;PEG-filgrastim;carboplatin;etoposide;cyclophosphamide;MESNA;doxorubicin
33 Adjuvant Treatment in Extensive Unilateral Retinoblastoma Primary Enucleated (RB SFCE 2009) Recruiting NCT02870907 Phase 2 Etoposide;Vincristine;Carboplatin;Vincristine;Cyclophosphamide;Carboplatin;Etoposide;Carboplatin;Thiotepa;Vincristine;Cyclophosphamide;Carboplatin;Etoposide;Thiotepa
34 Conservative Treatments of Retinoblastoma Recruiting NCT02866136 Phase 2 VP16, carboplatin;Melphalan;VP16, carboplatin, vincristin;Carboplatin + laser day 1 (chemothermotherapy);intravitreal Melphalan (local treatment)
35 Abemaciclib for Patients With Retinoblastoma-Positive, Triple Negative Metastatic Breast Cancer Recruiting NCT03130439 Phase 2 Abemaciclib
36 Anastrozole, Palbociclib, Trastuzumab and Pertuzumab in Her-positive, Her2-positive Metastatic Breast Recruiting NCT03304080 Phase 1, Phase 2 Anastrozole;Palbociclib;Trastuzumab;Pertuzumab
37 Enzalutamide With and Without Ribociclib for Metastatic, Castrate-Resistant, Chemotherapy-Naive Prostate Cancer That Retains RB Expression Recruiting NCT02555189 Phase 1, Phase 2 Enzalutamide;Ribociclib
38 Palbociclib With Cetuximab and IMRT for Locally Advanced Squamous Cell Carcinoma Recruiting NCT03024489 Phase 1, Phase 2 Palbociclib;Palbociclib;Palbociclib;Palbociclib;Cetuximab
39 Molecular Mechanisms of Resistance and Sensitivity to Palbociclib Re-challenge in ER+ mBC Recruiting NCT03184090 Phase 2 Palbociclib;Endocrine therapy (non IMP)
40 Combination Chemotherapy and Cyclosporine Followed by Focal Therapy for Bilateral Retinoblastoma Active, not recruiting NCT00110110 Phase 2 Carboplatin;Cyclosporine;Etoposide;vincristine sulfate
41 A Phase II Study of Androgen Deprivation Therapy With or Without Palbociclib in RB-Positive Metastatic Prostate Cancer Active, not recruiting NCT02059213 Phase 2 Ibrance;Bicalutamide;Zoladex;Lupron Depot
42 Iodine I 131 Monoclonal Antibody 3F8 in Treating Patients With Central Nervous System Cancer or Leptomeningeal Cancer Active, not recruiting NCT00445965 Phase 2
43 Intra-arterial Chemotherapy for the Treatment of Intraocular Retinoblastoma Terminated NCT01293539 Phase 2 Melphalan hydrochloride
44 Phase II Study Temozolomide for Retinoblastoma Metastatic to the Central Nervous System for Patients From Guatemala Terminated NCT01857752 Phase 2 Temozolomide
45 Proton Beam Radiation Therapy for Intraocular and Periocular Retinoblastoma Terminated NCT00432445 Phase 2
46 Intra-arterial Chemotherapy With Melphalan for the Treatment of Retinoblastoma (RTB) in Advanced Intraocular Stage Terminated NCT01393769 Phase 2 Melphalan
47 Phase II Trial of Palbociclib in Patients With Metastatic Urothelial Cancer After Failure of First-Line Chemotherapy Terminated NCT02334527 Phase 2 Palbociclib
48 A Pharmacodynamics Pre-surgical Study of LEE011 in Early Breast Cancer Patients (MONALEESA-1) Terminated NCT01919229 Phase 2 LEE011 (ribociclib);letrozole
49 Intra-arterial Chemotherapy for Advanced Intraocular Retinoblastoma Withdrawn NCT01151748 Phase 2
50 Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Children With Newly Diagnosed Brain Tumor Withdrawn NCT00003273 Phase 2 carboplatin;cisplatin;cyclophosphamide;etoposide;leucovorin calcium;methotrexate;temozolomide;thiotepa;vincristine sulfate

Search NIH Clinical Center for Retinal Cancer

Cochrane evidence based reviews: retinal neoplasms

Genetic Tests for Retinal Cancer

Anatomical Context for Retinal Cancer

MalaCards organs/tissues related to Retinal Cancer:

41
Retina, Eye, Lung, Skin, Liver, Bone, B Cells

Publications for Retinal Cancer

Articles related to Retinal Cancer:

# Title Authors Year
1
Maintenance of retinal cancer stem cell-like properties through long-term serum-free culture from human retinoblastoma. ( 21573498 )
2011
2
Intraperitoneal cultivation of small-cell carcinoma induces expression of the retinal cancer-associated retinopathy antigen. ( 8392328 )
1993

Variations for Retinal Cancer

Cosmic variations for Retinal Cancer:

9 (show all 45)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM1015 RB1 eye,retina,retinoblastoma,NS c.1215+1G>A p.? 13:48373493-48373493 6
2 COSM877 RB1 eye,retina,retinoblastoma,NS c.341C>A p.S114* 13:48342675-48342675 6
3 COSM910 RB1 eye,retina,retinoblastoma,NS c.1467C>A p.C489* 13:48380210-48380210 6
4 COSM5686463 RB1 eye,retina,retinoblastoma,NS c.1891C>T p.Q631* 13:48456280-48456280 6
5 COSM895 RB1 eye,retina,retinoblastoma,NS c.1363C>T p.R455* 13:48379624-48379624 6
6 COSM943 RB1 eye,retina,retinoblastoma,NS c.763C>T p.R255* 13:48362859-48362859 6
7 COSM13117 RB1 eye,retina,retinoblastoma,NS c.2053C>T p.Q685* 13:48459780-48459780 6
8 COSM891 RB1 eye,retina,retinoblastoma,NS c.958C>T p.R320* 13:48367512-48367512 6
9 COSM1636648 RB1 eye,retina,retinoblastoma,NS c.2106+2T>G p.? 13:48459835-48459835 6
10 COSM1014 RB1 eye,retina,retinoblastoma,NS c.1216-2A>G p.? 13:48376916-48376916 6
11 COSM888 RB1 eye,retina,retinoblastoma,NS c.1666C>T p.R556* 13:48381414-48381414 6
12 COSM938 RB1 eye,retina,retinoblastoma,NS c.967G>T p.E323* 13:48367521-48367521 6
13 COSM878 RB1 eye,retina,retinoblastoma,NS c.751C>T p.R251* 13:48362847-48362847 6
14 COSM887 RB1 eye,retina,retinoblastoma,NS c.1654C>T p.R552* 13:48381402-48381402 6
15 COSM317962 RB1 eye,retina,retinoblastoma,NS c.2106+1G>T p.? 13:48459834-48459834 6
16 COSM1026 RB1 eye,retina,retinoblastoma,NS c.2326-2A>C p.? 13:48465203-48465203 6
17 COSM903 RB1 eye,retina,retinoblastoma,NS c.1494T>A p.Y498* 13:48380237-48380237 6
18 COSM1013 RB1 eye,retina,retinoblastoma,NS c.1389+1G>C p.? 13:48379651-48379651 6
19 COSM876 RB1 eye,retina,retinoblastoma,NS c.160G>T p.E54* 13:48307302-48307302 6
20 COSM1030 RB1 eye,retina,retinoblastoma,NS c.1961-1G>A p.? 13:48459687-48459687 6
21 COSM1040 RB1 eye,retina,retinoblastoma,NS c.1960+2T>C p.? 13:48456351-48456351 6
22 COSM890 RB1 eye,retina,retinoblastoma,NS c.409G>T p.E137* 13:48345108-48345108 6
23 COSM911 RB1 eye,retina,retinoblastoma,NS c.1166T>A p.L389* 13:48373443-48373443 6
24 COSM889 RB1 eye,retina,retinoblastoma,NS c.2158A>T p.K720* 13:48463782-48463782 6
25 COSM880 RB1 eye,retina,retinoblastoma,NS c.1333C>T p.R445* 13:48379594-48379594 6
26 COSM3724517 RB1 eye,retina,retinoblastoma,NS c.862-5T>G p.? 13:48364889-48364889 6
27 COSM3724518 RB1 eye,retina,retinoblastoma,NS c.2520+4A>G p.? 13:48473394-48473394 6
28 COSM936 RB1 eye,retina,retinoblastoma,NS c.1183C>T p.Q395* 13:48373460-48373460 6
29 COSM144722 RB1 eye,retina,retinoblastoma,NS c.265-2A>C p.? 13:48342597-48342597 6
30 COSM1047 RB1 eye,retina,retinoblastoma,NS c.982A>C p.N328H 13:48367536-48367536 6
31 COSM942 RB1 eye,retina,retinoblastoma,NS c.2063T>C p.L688P 13:48459790-48459790 6
32 COSM5700369 RB1 eye,retina,retinoblastoma,NS c.2206C>T p.Q736* 13:48463830-48463830 6
33 COSM1041 RB1 eye,retina,retinoblastoma,NS c.1049+1G>T p.? 13:48367604-48367604 6
34 COSM1017 RB1 eye,retina,retinoblastoma,NS c.380+1G>T p.? 13:48342715-48342715 6
35 COSM3724510 RB1 eye,retina,retinoblastoma,NS c.2527G>T p.E843* 13:48476707-48476707 6
36 COSM1050 RB1 eye,retina,retinoblastoma,NS c.1421G>A p.S474N 13:48380084-48380084 6
37 COSM1016 RB1 eye,retina,retinoblastoma,NS c.1960+1G>A p.? 13:48456350-48456350 6
38 COSM882 RB1 eye,retina,retinoblastoma,NS c.2152G>A p.D718N 13:48463776-48463776 6
39 COSM764 PIK3CA eye,retina,retinoblastoma,NS c.1634A>G p.E545G 3:179218304-179218304 6
40 COSM520 KRAS eye,retina,retinoblastoma,NS c.35G>T p.G12V 12:25245350-25245350 6
41 COSM521 KRAS eye,retina,retinoblastoma,NS c.35G>A p.G12D 12:25245350-25245350 6
42 COSM5700368 eye,retina,retinoblastoma,NS c.2206C>T p.Q736* 13:48463830-48463830 6
43 COSM5686462 eye,retina,retinoblastoma,NS c.1891C>T p.Q631* 13:48456280-48456280 6
44 COSM5668651 eye,retina,retinoblastoma,NS c.2106+1G>T p.? 13:48459834-48459834 6
45 COSM5025108 eye,retina,retinoblastoma,NS c.763C>T p.R255* 13:48362859-48362859 6

Expression for Retinal Cancer

Search GEO for disease gene expression data for Retinal Cancer.

Pathways for Retinal Cancer

Pathways related to Retinal Cancer according to GeneCards Suite gene sharing:

(show top 50) (show all 112)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
14.29 CCND1 CCND3 CDK2 CDK4 CDKN1A CDKN1B
2
Show member pathways
14.09 CCND1 CCND3 CDK2 CDK4 CDK6 CDKN1A
3
Show member pathways
13.95 CCND1 CCND3 CDK2 CDK4 CDKN1A CDKN1B
4
Show member pathways
13.93 CDK2 CDKN1A CDKN1B CDKN2A E2F1 E2F4
5
Show member pathways
13.77 CCND1 CCND3 CDK2 CDK4 CDK6 CDKN1A
6
Show member pathways
13.42 CDK2 CDK4 CDK6 CDKN1A CDKN1B CDKN2A
7
Show member pathways
13.35 CCND1 CDKN1B E2F1 E2F2 E2F3 E2F4
8
Show member pathways
13.33 CCND1 CDK2 CDK4 CDK6 CDKN1A CDKN1B
9
Show member pathways
13.28 CCND1 CCND3 CDK2 CDK4 CDK6 CDKN1A
10
Show member pathways
13.23 CDK2 CDKN1A CDKN1B CDKN2A E2F1 E2F4
11 13.23 CCND1 CCND3 CDK2 CDK4 CDK6 CDKN1A
12
Show member pathways
13.21 CCND1 CDK2 CDK4 CDK6 CDKN1A CDKN1B
13
Show member pathways
13.12 CCND1 CCND3 CDK2 CDK4 CDK6 CDKN1A
14
Show member pathways
13.08 CCND1 CDK2 CDK4 CDKN1A CDKN1B E2F1
15
Show member pathways
13.04 CCND1 CDK2 CDK4 CDK6 CDKN1A CDKN1B
16
Show member pathways
13.03 CCND1 CDK2 CDK4 CDK6 CDKN1A CDKN1B
17
Show member pathways
12.97 CCND1 CCND3 CDK2 CDK4 CDK6 CDKN1B
18 12.97 CCND1 CCND3 CDK2 CDK4 CDK6 CDKN1A
19
Show member pathways
12.92 CCND1 E2F1 E2F3 MYC TP53
20
Show member pathways
12.9 CCND1 CCND3 CDK2 CDK4 CDK6 CDKN1A
21
Show member pathways
12.88 CDKN1A CDKN2A MDM2 MYC TP53
22 12.88 CCND1 CDK6 CDKN1A CDKN1B CDKN2A E2F1
23 12.86 CCND1 CCND3 CDK2 CDK4 CDK6 CDKN1A
24 12.78 CCND1 CCND3 CDK2 CDK4 CDK6 CDKN1A
25 12.76 CCND1 CCND3 CDK2 CDK4 CDK6 CDKN1A
26
Show member pathways
12.75 CCND1 CCND3 CDK2 CDK4 CDK6 CDKN1A
27
Show member pathways
12.74 CDK2 CDKN1A CDKN1B MDM2 TP53
28
Show member pathways
12.71 CCND1 CDKN1B MDM2 MYC RB1 TP53
29
Show member pathways
12.67 CCND1 CCND3 CDK2 CDK4 CDK6 CDKN1B
30
Show member pathways
12.66 CCND1 CDKN1A CDKN1B MDM2 MYC TP53
31
Show member pathways
12.65 CCND1 CCND3 CDKN1A CDKN1B MDM2 MYC
32 12.65 CCND1 CCND3 CDK2 CDK4 CDK6 E2F1
33
Show member pathways
12.64 CCND1 CCND3 CDK2 CDK4 CDK6 CDKN1A
34 12.64 CCND1 CCND3 CDK2 CDK4 CDK6 CDKN1A
35
Show member pathways
12.61 E2F1 E2F2 E2F3 E2F4 RB1
36 12.56 CCND1 CDK2 CDK4 CDK6 CDKN1A CDKN1B
37
Show member pathways
12.55 CCND1 CDK2 CDK4 CDK6 CDKN1A CDKN1B
38
Show member pathways
12.53 CCND1 CCND3 CDK2 CDK4 CDKN1A CDKN1B
39 12.52 CCND1 CCND3 CDK4 CDKN1A CDKN2A E2F1
40
Show member pathways
12.5 CDK2 CDKN1A CDKN1B RB1 TP53
41 12.48 CCND1 CDK2 CDK4 E2F1 MDM2 MYC
42 12.45 CCND1 CDKN1A MDM2 MYC TP53
43 12.42 CDKN1A CDKN1B MDM2 MYC TP53
44
Show member pathways
12.4 CCND1 CCND3 CDK2 CDK4 CDK6 E2F1
45 12.38 CCND1 CDKN1A E2F4 MYC RBL1 RBL2
46 12.38 CCND1 CCND3 CDKN1A CDKN1B CDKN2A MDM2
47 12.38 CCND1 CCND3 CDK2 CDK4 CDK6 CDKN1A
48 12.37 CCND1 CDK2 CDK4 CDKN1B E2F1 MYC
49 12.36 CCND1 CDKN1A E2F4 MYC TP53
50
Show member pathways
12.35 CCND1 CDK2 CDKN1A CDKN1B MDM2 RBL2

GO Terms for Retinal Cancer

Cellular components related to Retinal Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein-containing complex GO:0032991 9.91 CDK4 CDKN1A CDKN1B E2F1 MDM2 MYC
2 nuclear chromatin GO:0000790 9.76 E2F1 E2F4 MYC TP53
3 chromatin GO:0000785 9.71 CDK4 RB1 RBL1 RBL2
4 cyclin-dependent protein kinase holoenzyme complex GO:0000307 9.63 CCND1 CCND3 CDK2 CDK4 CDK6 CDKN1A
5 RNA polymerase II transcription factor complex GO:0090575 9.62 E2F1 E2F2 E2F3 E2F4
6 transcription factor complex GO:0005667 9.61 CDK2 CDK4 E2F1 E2F2 E2F3 E2F4
7 nucleoplasm GO:0005654 9.58 CCND1 CCND3 CDK2 CDK4 CDK6 CDKN1A
8 Rb-E2F complex GO:0035189 9.43 E2F1 RB1
9 nucleus GO:0005634 10.23 CCND1 CCND3 CDK2 CDK4 CDK6 CDKN1A
10 nucleolus GO:0005730 10.02 CDK4 CDKN1A CDKN2A MDM2 MYC RBL2

Biological processes related to Retinal Cancer according to GeneCards Suite gene sharing:

(show top 50) (show all 63)
# Name GO ID Score Top Affiliating Genes
1 cell cycle arrest GO:0007050 9.97 CDK6 CDKN1A CDKN1B CDKN2A CDKN3 MYC
2 cellular response to hypoxia GO:0071456 9.96 E2F1 MDM2 MYC TP53
3 negative regulation of cell growth GO:0030308 9.95 CDKN1A CDKN1B CDKN2A TP53
4 response to toxic substance GO:0009636 9.9 CDK4 CDKN1A MDM2
5 response to organic substance GO:0010033 9.9 CCND1 CDK4 CDKN1A
6 regulation of signal transduction by p53 class mediator GO:1901796 9.89 CDK2 MDM2 TP53
7 Ras protein signal transduction GO:0007265 9.89 CDK2 CDKN1A CDKN2A RB1 TP53
8 cellular response to organic cyclic compound GO:0071407 9.88 CDKN1B MDM2 MYC
9 negative regulation of epithelial cell proliferation GO:0050680 9.88 CDK6 CDKN1B RB1
10 negative regulation of G1/S transition of mitotic cell cycle GO:2000134 9.88 CDKN1A RB1 RBL1 RBL2
11 positive regulation of fibroblast proliferation GO:0048146 9.88 CDK4 CDK6 CDKN1A E2F1 MYC
12 positive regulation of cell cycle GO:0045787 9.88 CCND1 CCND3 CDK4 CDKN1B MDM2 MYC
13 DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrest GO:0006977 9.86 CDK2 CDKN1A CDKN1B E2F1 E2F4 MDM2
14 animal organ regeneration GO:0031100 9.85 CCND1 CDK4 CDKN1A
15 negative regulation of cell cycle GO:0045786 9.85 CDK6 CDKN1B RB1
16 regulation of cyclin-dependent protein serine/threonine kinase activity GO:0000079 9.85 CCND1 CCND3 CDKN1A CDKN1B CDKN3
17 regulation of mitotic cell cycle GO:0007346 9.83 CDKN1A MYC RB1 RBL1 RBL2
18 positive regulation of cyclin-dependent protein serine/threonine kinase activity GO:0045737 9.82 CCND1 CCND3 CDKN1B
19 intrinsic apoptotic signaling pathway by p53 class mediator GO:0072332 9.81 E2F1 E2F2 TP53
20 negative regulation of cyclin-dependent protein serine/threonine kinase activity GO:0045736 9.81 CDKN1A CDKN1B CDKN2A
21 negative regulation of cell cycle arrest GO:0071157 9.8 CCND1 CDK4 MDM2
22 negative regulation of phosphorylation GO:0042326 9.79 CDKN1A CDKN1B CDKN2A
23 replicative senescence GO:0090399 9.77 CDKN1A CDKN2A TP53
24 mitotic G1 DNA damage checkpoint GO:0031571 9.74 CCND1 CDK2 TP53
25 cellular response to estrogen stimulus GO:0071391 9.73 MDM2 MYC
26 determination of adult lifespan GO:0008340 9.73 PRDM2 TP53
27 regulation of G1/S transition of mitotic cell cycle GO:2000045 9.73 CCND1 E2F1
28 response to hyperoxia GO:0055093 9.73 CDK4 CDKN1A
29 response to magnesium ion GO:0032026 9.72 CCND1 MDM2
30 regulation of insulin receptor signaling pathway GO:0046626 9.72 CCND3 CDK4
31 cellular response to antibiotic GO:0071236 9.72 CDKN1B MDM2
32 obsolete negative regulation of cyclin-dependent protein serine/threonine kinase activity involved in G1/S transition of mitotic cell cycle GO:0031658 9.72 CDK4 CDK6 CDKN2A
33 amyloid fibril formation GO:1990000 9.71 CDKN2A MDM2
34 regulation of cell division GO:0051302 9.71 RBL1 RBL2
35 negative regulation of monocyte differentiation GO:0045656 9.7 CDK6 MYC
36 regulation of lipid kinase activity GO:0043550 9.7 RB1 RBL1 RBL2
37 regulation of cell cycle GO:0051726 9.7 CCND1 CCND3 CDK2 CDK4 E2F1 E2F2
38 cellular response to phorbol 13-acetate 12-myristate GO:1904628 9.69 CDK4 MYC
39 re-entry into mitotic cell cycle GO:0000320 9.69 CCND1 MYC
40 cellular response to xenobiotic stimulus GO:0071466 9.69 E2F1 RB1
41 negative regulation of fat cell proliferation GO:0070345 9.68 E2F1 E2F3
42 signal transduction by p53 class mediator GO:0072331 9.68 CDKN1A TP53
43 lens fiber cell apoptotic process GO:1990086 9.67 E2F1 E2F2
44 negative regulation of cyclin-dependent protein kinase activity GO:1904030 9.67 CDKN1A CDKN1B
45 cellular response to actinomycin D GO:0072717 9.66 MDM2 TP53
46 negative regulation of transcription involved in G1/S transition of mitotic cell cycle GO:0071930 9.66 E2F1 RB1
47 G1/S transition of mitotic cell cycle GO:0000082 9.32 CCND1 CDK2 CDK4 CDK6 CDKN1A CDKN1B
48 regulation of transcription, DNA-templated GO:0006355 10.3 E2F1 E2F2 E2F3 E2F4 MYC PRDM2
49 positive regulation of transcription by RNA polymerase II GO:0045944 10.21 CDKN2A E2F1 E2F2 E2F3 E2F4 MYC
50 positive regulation of transcription, DNA-templated GO:0045893 10.16 CDK2 CDKN2A E2F1 E2F3 MYC RB1

Molecular functions related to Retinal Cancer according to GeneCards Suite gene sharing:

(show all 22)
# Name GO ID Score Top Affiliating Genes
1 proximal promoter DNA-binding transcription activator activity, RNA polymerase II-specific GO:0001077 9.97 E2F1 E2F2 E2F3 E2F4 MYC
2 protein-containing complex binding GO:0044877 9.97 CCND1 CDK4 CDKN1A CDKN1B MYC
3 protein kinase binding GO:0019901 9.95 CCND1 CCND3 CDKN1A CDKN1B CDKN2A E2F1
4 protein dimerization activity GO:0046983 9.93 E2F1 E2F2 E2F3 E2F4 MYC
5 DNA-binding transcription activator activity, RNA polymerase II-specific GO:0001228 9.92 E2F2 E2F3 E2F4 PRDM2 TP53
6 ubiquitin protein ligase binding GO:0031625 9.91 CDKN1A MDM2 RB1 TP53
7 RNA polymerase II activating transcription factor binding GO:0001102 9.76 RB1 RBL1 RBL2
8 cyclin-dependent protein serine/threonine kinase regulator activity GO:0016538 9.73 CCND1 CCND3 CDK4
9 promoter-specific chromatin binding GO:1990841 9.73 E2F4 RBL1 RBL2 TP53
10 proximal promoter DNA-binding transcription repressor activity, RNA polymerase II-specific GO:0001078 9.7 E2F1 E2F2 E2F3 E2F4 RB1 RBL1
11 cyclin-dependent protein serine/threonine kinase inhibitor activity GO:0004861 9.67 CDKN1A CDKN1B CDKN2A
12 disordered domain specific binding GO:0097718 9.67 CDKN2A MDM2 RB1 TP53
13 transcription factor binding GO:0008134 9.65 CCND1 CDKN2A E2F1 E2F2 E2F3 E2F4
14 RNA polymerase II regulatory region DNA binding GO:0001012 9.63 RB1 RBL1 RBL2
15 proximal promoter sequence-specific DNA binding GO:0000987 9.62 E2F1 E2F2 E2F3 RB1
16 cyclin binding GO:0030332 9.56 CDK2 CDK4 CDK6 CDKN1B
17 cyclin-dependent protein serine/threonine kinase activity GO:0004693 9.17 CCND1 CCND3 CDK2 CDK4 CDK6 CDKN1A
18 protein binding GO:0005515 10.45 CCND1 CCND3 CDK2 CDK4 CDK6 CDKN1A
19 DNA binding GO:0003677 10.25 CDKN2A E2F1 E2F2 E2F3 E2F4 MYC
20 DNA-binding transcription factor activity GO:0003700 10.11 E2F1 E2F2 E2F3 E2F4 MYC PRDM2
21 sequence-specific DNA binding GO:0043565 10.07 E2F1 E2F2 E2F3 E2F4 MYC PRDM2
22 protein kinase activity GO:0004672 10 CCND1 CCND3 CDK2 CDK4 CDK6

Sources for Retinal Cancer

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....